Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript
Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
Stay updated with breaking news from Michael Schumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.
/PRNewswire/ -- A news report from Shenzhen Daily: During a 10-day business promotion trip to Europe, a delegation from Shenzhen's Guangming District reached...
Issuer: Immunic, Inc. / Key word(s): Miscellaneous Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need 09.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Host Virtu...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...